Table 3.
Pre- and intraoperative data of IBD-related surgeries.
| Variable | Total (n = 61) |
|---|---|
| Age at surgery, y, median (range) | 13.6 (4.6–17.8) |
| Age at IBD onset, y, median (range) | 10.2 (0.6–16.8) |
| BMI, n (%) | |
| <−2 SD | 14 (23) |
| −1.9–+1.9 SD | 46 (75.4) |
| >+2 SD | 1 (1.6) |
| Indication, n (%) | |
| UC | 28 (45.9) |
| CD | 28 (45.9) |
| CD-like IBDU | 3 (4.9) |
| UC-like IBDU | 2 (3.3) |
| Drugs, n (%) | |
| None | 27 (44.3) |
| Steroids | 6 (9.8) |
| Biologics a | 18 (29.5) |
| Both | 10 (16.4) |
| Nutritional support, n (%) | |
| No | 47 (77) |
| Enteral nutrition b | 8 (13.1) |
| Parenteral nutrition | 4 (6.6) |
| Both | 2 (3.3) |
| Approach, n (%) | |
| Laparoscopy | 57 (93.4) |
| Laparotomy | 4 (6.6) |
| Type, n (%) | |
| Proctocolectomies with ileal pouch anal-anastomosis with ileostomy | 19 |
| Ileostomy closures | 16 |
| Subtotal colectomies with ileostomy | 14 |
| Terminal ileostomies | 5 |
| Ileocecal resections without ileostomy | 5 |
| Ileocecal resection with ileostomy | 1 |
IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; IBDU, IBD unclassified; SD, standard deviation. a anti-tumor necrosis factor-α agents. b Impact®, Nestlé Health Science, Switzerland.